专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

ZA200105908B Electronic data storage and display apparatus. 未知
公开(公告)号：ZA200105908B
公开(公告)日：2002-02-21
申请号：ZA200105908
申请日：2001-07-18
申请人： MICHAEL JARMAN DAVID
发明人： MICHAEL JARMAN DAVID
IPC分类号： G06F1/00 , G06F12/14 , G06F21/10 , G06F

2. 发明申请

US20090325983A1 NEW PURINE DERIVATIVES 有权
标题翻译：新的嘌呤衍生物
公开(公告)号：US20090325983A1
公开(公告)日：2009-12-31
申请号：US12489663
申请日：2009-06-23
申请人： Peter Martin FISCHER , Michael JARMAN , Edward MCDONALD , Bernard NUTLEY , Florence RAYNAUD , Stuart WILSON , Paul WORKMAN
发明人： Peter Martin FISCHER , Michael JARMAN , Edward MCDONALD , Bernard NUTLEY , Florence RAYNAUD , Stuart WILSON , Paul WORKMAN
IPC分类号： A61K31/52 , C07D473/16 , C12Q1/48
CPC分类号： C07D473/16 , A61K31/52 , Y02A50/411
摘要： The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.
摘要翻译：本发明涉及式1化合物或其药学上可接受的盐，其中R 1和R 2之一是甲基，乙基或异丙基，另一个是H; R 3和R 4各自独立地为H，支链或非支链的C 1 -C 6烷基或芳基，并且其中R 3和R 4中的至少一个不是H; R5是支链或非支链C 1 -C 5烷基或C 1 -C 6环烷基，其各自可以任选被一个或多个OH基取代; R6，R7，R8和R9各自独立地为H，卤素，NO2，OH，OMe，CN，NH2，COOH，CONH2或SO2NH2。本发明的另一方面涉及包含式1化合物的药物组合物，以及所述化合物在治疗增殖性疾病，病毒性疾病，中风，脱发，中枢神经系统疾病，神经变性疾病或糖尿病中的用途。

3. 发明授权

US5854244A Melamine derivatives for use in the treatment of cancer 失效
标题翻译：用于治疗癌症的三聚氰胺衍生物
公开(公告)号：US5854244A
公开(公告)日：1998-12-29
申请号：US631659
申请日：1996-04-02
申请人： Michael Jarman , Helen Mary Coley
发明人： Michael Jarman , Helen Mary Coley
IPC分类号： A61K31/53 , A61P35/00 , C07D251/70
CPC分类号： C07D251/70
摘要： The present invention provides compounds of the formula (I) wherein each R.sup.1, which may be the same or different, is hydrogen, C.sub.1-4 alkyl, or an electron withdrawing group selected from the group consisting of CF.sub.3 CH.sub.2 or CH.sub.2 C.tbd.CH, R.sup.2 is hydrogen, C.sub.1-4 alkyl, or an electron withdrawing group selected from the group consisting of CF.sub.3 CH.sub.2 or CH.sub.2 C.tbd.CH. The compounds are analogs of trimelamol which have comparable activity but enhanced stability, and are useful as anticancer agents, particularly against ovarian cancer.
摘要翻译：本发明提供式（I）化合物，其中每个可以相同或不同的R 1是氢，C 1-4烷基或选自CF 3 CH 2或CH 2 C 3 CH 2的吸电子基团，R 2是氢，C 1-4烷基或选自CF 3 CH 2或CH 2 C 3 CH 3的吸电子基团。这些化合物是具有相当活性但增强稳定性的三聚木酚类似物，并且可用作抗癌剂，特别是抗卵巢癌。

4. 发明授权

US5716990A Drug delivery systems 失效
标题翻译：药物输送系统
公开(公告)号：US5716990A
公开(公告)日：1998-02-10
申请号：US709740
申请日：1996-09-09
申请人： Kenneth D. Bagshawe , Michael Jarman , Caroline Joy Springer
发明人： Kenneth D. Bagshawe , Michael Jarman , Caroline Joy Springer
IPC分类号： A61K47/48 , A61K31/255 , C07C231/02 , C07C309/06
CPC分类号： B82Y5/00 , A61K47/48761
摘要： Nitrogen mustard pro-drugs of the formula ##STR1## are disclosed where R is the residue of an .alpha.-amino acid RNH.sub.2 and M is a disubstituted amino "mustard" group, useful in antibody directed enzyme pro-drug therapy in the treatment of cancer.
摘要翻译：公开了具有式“IMAGE”的氮芥前体药物，其中R是α-氨基酸RNH2的残基，M是二取代的氨基“芥子”基团，可用于治疗癌症中的抗体定向酶前药治疗。

5. 发明授权

US5071857A 2,6-dioxopiperidine derivatives, their preparation and pharmaceutical compositions containing them 失效
标题翻译： 2,6-二氧代哌啶衍生物，其制备和含有它们的药物组合物
公开(公告)号：US5071857A
公开(公告)日：1991-12-10
申请号：US571830
申请日：1990-08-22
申请人： Allan B. Foster , Michael Jarman , Grahame N. Taylor , Chui-Sheung Kwan
发明人： Allan B. Foster , Michael Jarman , Grahame N. Taylor , Chui-Sheung Kwan
IPC分类号： C07D213/57 , C07D401/04
CPC分类号： C07D401/04 , C07D213/57
摘要： In the treatment of oestrogen-dependent tumors, it is desirable to improve the therapy obtainable from the compound aminoglutethimide. It has now been found that 3-ethyl-3-(4-pyridyl)glutarimide and derivatives thereof of formula ##STR1## wherein R represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms offers advantages over aminoglutethimide. 3-Ethyl-3-(4-pyridyl)glutarimide can be prepared by various ring-closing reactions, especially by heating 4-(4-pyridyl)-hexano-1,4-dinitrile with a strong mineral acid.
摘要翻译： PCT No.PCT / GB84 / 00425 Sec。 371日期：1985年7月16日 102（e）日期1985年7月16日PCT提交1984年12月10日PCT公布。出版物WO85 / 02618 1985年6月20日。在治疗雌激素依赖性肿瘤时，期望改善从化合物氨基丁二酰亚胺获得的治疗。现已发现3-氨基-3-（4-吡啶基）戊二酰亚胺及其衍生物，其中R表示氢原子或具有1-4个碳原子的烷基，具有优于氨基异丁酰亚胺的优点。 3-乙基-3-（4-吡啶基）戊二酰亚胺可以通过各种闭环反应制备，特别是通过用强无机酸加热4-（4-吡啶基） - 己酰-1,4-二腈。

6. 发明授权

US08725657B2 Utility metering system incorporating a transaction authorisation system 失效
标题翻译：包含交易授权系统的公用计量系统
公开(公告)号：US08725657B2
公开(公告)日：2014-05-13
申请号：US09862917
申请日：2001-05-22
申请人： Michael Jarman , Gavin Howard
发明人： Michael Jarman , Gavin Howard
IPC分类号： G06F17/00 , G06Q40/00
CPC分类号： G06Q20/4016 , G06Q20/127 , G06Q20/145 , G06Q20/202 , G06Q20/28 , G06Q20/3224 , G06Q20/341 , G06Q20/4012 , G06Q20/409 , G06Q50/06 , G07F7/1008 , G07F15/003
摘要： A transaction authorization system comprises a user interface unit 30 capable of accepting a transaction authorization and a utility meter 10 provided at a location having an associated location identifier unique to the location, wherein the utility meter 10 is arranged to communicate with the user interface unit 10, to obtain a transaction authorization, and to transmit an authorization request based on the transaction authorization and location identifier to obtain authorization of the transaction.
摘要翻译：交易授权系统包括能够接受交易授权的用户接口单元30和设置在具有该位置所特有的相关联的位置标识符的位置的公用事业仪表10，其中公用事业仪表10被布置为与用户接口单元10通信，以获得交易授权，并且基于交易授权和位置标识符传送授权请求以获得交易的授权。

7. 发明申请

US20130218771A1 ELECTRONIC PAYMENT UNIT, ELECTRONIC PAYMENT ORIGIN AUTHENTICATION SYSTEM AND METHOD 审中-公开
标题翻译：电子支付单位，电子支付原件认证系统及方法
公开(公告)号：US20130218771A1
公开(公告)日：2013-08-22
申请号：US13699513
申请日：2011-05-24
申请人： Michael Jarman
发明人： Michael Jarman
IPC分类号： G06Q20/34
CPC分类号： G06Q20/34 , G06Q20/12 , G06Q20/382 , G06Q20/40 , G07C9/00111 , G07F7/088 , G07F7/12
摘要： An electronic payment unit including includes a data communications interface, a payment card reader and a memory. During a registration process between the electronic payment unit and a registering system at a location having a unique identifier associated with the location, the electronic payment unit is operative to store the unique identifier, or data derived from or including the unique identifier in the memory. The payment card reader is arranged to read a payment card during an electronic transaction, and to form for transmission, via the data communications interface, an electronic payment request including data on the payment card and on the content of the memory. An associated system and method are also disclosed.
摘要翻译：一种电子支付单元，包括数据通信接口，支付卡读卡器和存储器。在电子支付单元与具有与该位置相关联的唯一标识符的位置处的注册系统之间的注册过程中，电子支付单元可操作以将唯一标识符或从该唯一标识符导出或包括该唯一标识符的数据存储在存储器中。支付卡读卡器被安排为在电子交易期间读取支付卡，并且通过数据通信接口形成用于传输包括支付卡上的数据和存储器的内容的电子支付请求。还公开了一种相关联的系统和方法。

8. 发明授权

US07582642B2 Purine derivatives 有权
标题翻译：嘌呤衍生物
公开(公告)号：US07582642B2
公开(公告)日：2009-09-01
申请号：US11033692
申请日：2005-01-11
申请人： Peter Martin Fischer , Michael Jarman , Edward McDonald , Bernard Nutley , Florence Raynaud , Stuart Wilson , Paul Workman
发明人： Peter Martin Fischer , Michael Jarman , Edward McDonald , Bernard Nutley , Florence Raynaud , Stuart Wilson , Paul Workman
IPC分类号： C07D473/16 , A61K31/52 , A61P35/00 , A61P31/14 , A61P31/20 , C07D473/40
CPC分类号： C07D473/16 , A61K31/52 , Y02A50/411
摘要： The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.
摘要翻译：本发明涉及式1化合物或其药学上可接受的盐，其中R 1和R 2之一是甲基，乙基或异丙基，另一个是H; R 3和R 4各自独立地为H，支链或非支链的C 1 -C 6烷基或芳基，并且其中R 3和R 4中的至少一个不是H; R5是支链或非支链C 1 -C 5烷基或C 1 -C 6环烷基，其各自可以任选被一个或多个OH基取代; R6，R7，R8和R9各自独立地为H，卤素，NO2，OH，OMe，CN，NH2，COOH，CONH2或SO2NH2。本发明的另一方面涉及包含式1化合物的药物组合物，以及所述化合物在治疗增殖性疾病，病毒性疾病，中风，脱发，中枢神经系统疾病，神经变性疾病或糖尿病中的用途。

9. 发明申请

US20060183760A1 New purine derivatives 有权
标题翻译：新嘌呤衍生物
公开(公告)号：US20060183760A1
公开(公告)日：2006-08-17
申请号：US11238533
申请日：2005-09-28
申请人： Peter Fischer , Michael Jarman , Edward McDonald , Bernard Nutley , Florence Raynaud , Stuart Wilson , Paul Workman
发明人： Peter Fischer , Michael Jarman , Edward McDonald , Bernard Nutley , Florence Raynaud , Stuart Wilson , Paul Workman
IPC分类号： A61K31/52 , C07D473/12
CPC分类号： C07D473/16
摘要： The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.
摘要翻译：本发明涉及式I化合物或其药学上可接受的盐，其中R 1和R 2中的一个为甲基，乙基或异丙基，另一个为H; R 3和R 4各自独立地为H，支链或非支链C 1 -C 6烷基，或芳基，并且其中R 3和R 4中的至少一个不是H; R 5是支链或非支链C 1 -C 5烷基或C 1 -C 3亚烷基其中每一个可以任选地被一个或多个OH基团取代; R 6，R 7，R 8和R 9各自独立地为H，卤素，NO 3， 2，OH，OMe，CN，NH 2，COOH，CONH 2或SO 2 NH 2， / SUB>。本发明的另一方面涉及包含式1化合物的药物组合物，以及所述化合物在治疗增殖性疾病，病毒性疾病，中枢神经系统疾病，糖尿病，中风，脱发或神经变性疾病中的用途。

10. 发明授权

US5595995A Pyridyl-propan-2-yl esters of 1-adamantane carboxylates 失效
标题翻译： 1-金刚烷羧酸酯的吡啶基 - 丙-2-基酯
公开(公告)号：US5595995A
公开(公告)日：1997-01-21
申请号：US335743
申请日：1995-01-18
申请人： Ferdinand Chan , Michael Jarman , Gerard A. Potter
发明人： Ferdinand Chan , Michael Jarman , Gerard A. Potter
IPC分类号： C07D213/30 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61P3/00 , A61P5/28 , A61P13/02 , A61P13/08 , A61P15/00 , A61P35/00 , C07D213/50 , C07D213/55
CPC分类号： C07D213/50 , C07D213/55
摘要： Compounds having the general formula: ##STR1## wherein each of R.sup.1 and R.sup.2 independently represents hydrogen or alkyl of 1 to 4 carbon atoms;A represents --O-- or --CR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are defined as for R.sup.1 or R.sup.2 ;R.sup.3 represents an adamantyl group; andPy represents a 3- or 4-pyridyl group, as free bases or their pharmaceutically acceptable salts are useful in treating androgen-dependent, especially prostatic, cancer.
摘要翻译： PCT No.PCT / GB93 / 00890 Sec。 371 1995年1月18日第 102（e）日期1995年1月18日PCT提交1993年4月29日PCT公布。公开号WO93 / 23375 日期：1993年11月25日具有以下通式的化合物：其中R 1和R 2各自独立地表示氢或1至4个碳原子的烷基; A表示-O-或-CR4R5，其中R4和R5定义为R1或R2; R3表示金刚烷基; 并且Py代表3-或4-吡啶基，因为游离碱或其药学上可接受的盐可用于治疗雄激素依赖性，特别是前列腺癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式